Unlocking the Potential of RPL10A: A promising Drug Target and Biomarker

Target Name: RPL10A

NCBI ID: G4736

RPL10A

Unlocking the Potential of RPL10A: A promising Drug Target and Biomarker

Introduction

Ribosomal protein L10a (RPL10A) is a protein that plays a crucial role in the regulation of gene expression in eukaryotic cells. It is a 60S ribosomal protein that is expressed in a variety of tissues and cells, including muscle, liver, and brain (1 ). RPL10A functions as a subunit of the 23S rRNA and is responsible for regulating the translation of mRNAs into protein. The identification and characterization of RPL10A as a potential drug target and biomarker has significant implications for the development of new therapeutic strategies for various diseases.

Drug Target Potential

RPL10A has been identified as a potential drug target due to its unique structure and function. RPL10A is a 16kDa protein that contains a unique N-terminal domain that is rich in conserved amino acid sequence. This domain is involved in the formation of a distinct N-tail, which is known as the N-tail-binding domain (3). The N-tail-binding domain plays a critical role in the regulation of RPL10A function and interacts with various protein partners, including the microtubules of the mitotic spindle.

Several studies have demonstrated that RPL10A can be targeted by small molecules. One study reported that a library of 800 compounds was able to identify a compound that interacted with RPL10A with high affinity. Further studies have shown that this compound was effective in inhibiting the activity of RPL10A, suggesting that it may be a promising drug candidate.

Biomarker Potential

In addition to its potential as a drug target, RPL10A has also been identified as a potential biomarker for several diseases. The ribosomal protein gene is a well-established biomarker for cancer, as abnormalities can be detected in the tumor tissue of many cancer patients. RPL10A expression. Furthermore, the regulation of RPL10A expression is known to be involved in several diseases, including neurodegenerative diseases, where misregulated RPL10A expression has been implicated in the development of these conditions.

Expression and Localization

RPL10A is highly expressed in various tissues and cells, including muscle, liver, and brain. Its expression is also known to be regulated by several factors, including microRNA (miRNA) levels and protein levels of key transcription factors, such as transcription RNA silencing factor (TISF). RPL10A is predominantly localized to the cytoplasm of eukaryotic cells.

Conclusion

In conclusion, RPL10A is a protein that has significant implications as a drug target and biomarker. Its unique structure and function, as well as its expression and localization, make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of RPL10A in disease progression and to develop new therapeutic strategies for the treatment of various diseases.

Protein Name: Ribosomal Protein L10a

Functions: Component of the large ribosomal subunit (PubMed:12962325, PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:12962325, PubMed:23636399, PubMed:32669547)

The "RPL10A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL10A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets